Sõda

MEEDIAVALVUR: algab „sõjalise erioperatsiooni“ teine etapp nimega „SÕDA“

DODC is a psychedelic drug from the substituted amphetamine family which acts as an agonist of the 5-HT2A receptor. It is the 3,4-dichloro derivative of the well known psychedelic drug 2,5-Dimethoxy-4-chloroamphetamine (DOC). DODC was first officially published in a patent filed by Gilgamesh Pharmaceuticals in 2020,[1] though anecdotal reports suggest it had been synthesised by clandestine chemists and its activity established several years prior to this.

See also

References

  1. ^ WO 2022/006186, Kruegel AC, "Phenalkylamines and Methods of Treating Mood Disorders.", published January 2022, assigned to Gilgamesh Pharmaceuticals. 



Kommenteeri